Amount of liability recognized from contingent consideration in asset acquisition, classified as noncurrent.

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 805
-SubTopic 50
-Name Accounting Standards Codification
-Section 15
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480123/805-50-15-3

+ Details

Name:	us-gaap_AssetAcquisitionContingentConsiderationLiabilityNoncurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Aggregate carrying value as of the balance sheet date of the liabilities for stock option plans and other equity-based compensation arrangements payable within one year (or the operating cycle, if longer).

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(20))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

+ Details

Name:	us-gaap_DeferredCompensationShareBasedArrangementsLiabilityCurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 100
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482078/820-10-55-100

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-3

+ Details

Name:	us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of increase (decrease) in the value during the period from contingent consideration liability.

+ References

No definition available.

+ Details

Name:	xoma_AssetAcquisitionContingentConsiderationLiabilityChangeInAmount
Namespace Prefix:	xoma_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Fair value of investment in warrants, classified as noncurrent.

+ References

No definition available.

+ Details

Name:	xoma_InvestmentWarrantsNoncurrent
Namespace Prefix:	xoma_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Amount of increase (decrease) in the value during the period of milestone assets. Amount represents initial fair value in accordance with ASC 825.

+ References

No definition available.

+ Details

Name:	xoma_MilestoneAssetsIncreaseDecrease
Namespace Prefix:	xoma_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Carrying amount as of the balance sheet date of milestone assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer. Amount represents initial fair value in accordance with ASC 825.

+ References

No definition available.

+ Details

Name:	xoma_MilestoneAssetsNoncurrent
Namespace Prefix:	xoma_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

The rights entity acquired as a percentage of specified percentage of net sales or as a specified percentage of proceeds from potential Priority Review Voucher.

+ References

No definition available.

+ Details

Name:	xoma_RightsReceivablePercentageOnNetSalesAndProceeds
Namespace Prefix:	xoma_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=xoma_KinnateCvrHoldersMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=xoma_ContingentValueRightsAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=xoma_CastleCreekBiosciencesIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=xoma_RoyaltyFinancingAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Fair Value Measurements - Milestone Asset, Milestone Contingent Consideration and PRV Interest and Warrants (Details) - USD ($) $ in Thousands	1 Months Ended	12 Months Ended
	Feb. 28, 2025	Dec. 31, 2025	Dec. 31, 2024
Fair Value Measurements
Exarafenib milestone asset (Note 6)		$ 3,600	$ 3,214
Exarafenib milestone contingent consideration		3,600	3,214
Fair value of warrants		697
Fair value of the share-based liability		3,197
Level 3
Fair Value Measurements
Fair value of the share-based liability		3,200
Kinnate CVR holders \| CVR Agreement
Fair Value Measurements
Exarafenib milestone asset (Note 6)		3,600
Exarafenib milestone contingent consideration		3,600	$ 3,200
Increase in Exarafenib milestone asset		400
Increase in Exarafenib milestone contingent consideration		400
Castle Creek Biosciences, Inc \| Royalty Financing Transaction
Fair Value Measurements
Rights entity acquired as a percentage of specified percentage	6.70%
Fair value of warrants	$ 700	$ 700